Previous Article | Next Article 
Infection and Immunity, March 2001, p. 1774-1780, Vol. 69, No. 3
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.3.1774-1780.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Expression of Adhesion Molecules in Synovia of
Patients with Treatment-Resistant Lyme Arthritis
Evren
Akin,1,2,*
John
Aversa,3 and
Allen C.
Steere1
Divisions of
Rheumatology/Immunology1 and Pediatric
Rheumatology,2 Tufts University School of
Medicine, New England Medical Center, Boston, Massachusetts, and
the New Haven Orthopedic Group, New Haven,
Connecticut3
Received 28 August 2000/Returned for modification 11 October
2000/Accepted 8 December 2000
 |
ABSTRACT |
The expression of adhesion molecules in synovium in patients with
Lyme arthritis is surely critical in the control of Borrelia burgdorferi infection but may also have pathologic consequences. For example, molecular mimicry between a dominant T-cell epitope of
B. burgdorferi outer surface protein A and an adhesion
molecule, human lymphocyte function-associated antigen 1 (LFA-1), has
been implicated in the pathogenesis of treatment-resistant Lyme
arthritis. Using immunohistochemical methods, we examined synovial
samples for expression of adhesion molecules in 29 patients with
treatment-resistant Lyme arthritis and in 15 patients with rheumatoid
arthritis or chronic inflammatory monoarthritis. In Lyme arthritis
synovia, endothelial cells showed intense expression of P-selectin and vascular adhesion protein-1 (VAP-1). Expression of LFA-1 was also intense on infiltrating cells, particularly in lymphoid aggregates, and
intercellular adhesion molecule-1 (ICAM-1) was markedly expressed on
synovial lining and endothelial and infiltrating cells. Moderate expression of vascular cell adhesion molecule-1 (VCAM-1) was seen on
synovial lining and endothelial cells, and mild expression of its
ligand, very late antigen-4, was apparent in perivascular lymphoid
infiltrates. Except for lesser expression of VCAM-1 in Lyme synovia,
the levels of expression of these adhesion molecules were similar in
the three patient groups. We conclude that certain adhesion molecules,
including ICAM-1 and LFA-1, are expressed intensely in the synovia of
patients with Lyme arthritis. Upregulation of LFA-1 on lymphocytes in
this lesion may be critical in the pathogenesis of treatment-resistant
Lyme arthritis.
 |
INTRODUCTION |
Lyme disease worldwide is caused by
three genospecies of the tick-borne spirochete Borrelia
burgdorferi sensu lato (11). In the United States,
where the infection is caused by B. burgdorferi sensu
stricto strains, intermittent or chronic oligoarticular arthritis
primarily affecting large joints, especially the knees, is a
prominent late manifestation of the illness (33-35).
Although most patients with Lyme arthritis can be treated effectively
with antibiotic therapy, about 10% of patients have persistent knee swelling for months to years after
2 months of oral antibiotics or
1 month of intravenous antibiotics. This condition has been termed
antibiotic treatment-resistant Lyme arthritis.
Adhesion molecules in inflammatory foci have three important cellular
functions: homing to lymphoid tissues, migration to inflammatory sites,
and costimulation of cellular activation (23). There are
four major structural classes of adhesion molecules (reviewed by
Janeway et al. and McMurray [18, 21]). The selectins and
vascular addressins mediate the initial phases of extravasation, which
cause the tethering and rolling of leukocytes on endothelial surfaces
(31). Leukocyte integrins, including lymphocyte function associated antigen-1 (LFA-1 [
L
2]) and very late antigen-4
(VLA-4 [
4
1]), bind to their ligands of the immunoglobulin
superfamily, intercellular adhesion molecule-1 (ICAM-1) and vascular
cell adhesion molecule-1 (VCAM-1), respectively (1, 18,
22). These interactions attach leukocytes firmly to endothelial
surfaces. Binding of these adhesion molecules also mediates
intercellular communication in inflammatory foci. For example, the
interaction of LFA-1 on T cells with its main ligand, ICAM-1, on
macrophages anchors the cells together and provides a potent
costimulatory signal for T-cell activation (18).
In addition to having standard functions, host adhesion molecules seem
to have specific consequences in the pathogenesis of B. burgdorferi infection. The spirochete attaches to the
platelet-specific integrin receptor
(
IIb
3), also known as the fibrinogen
receptor, which is expressed only on activated platelets
(9). This mechanism may aid the spirochete in homing to
sites of endothelial cell injury. In addition, the spirochete binds the
ubiquitous vitronectin (
v
3) and fibronectin (
5
1) receptors
(10) and attaches to various proteoglycans, including
decorin, which decorates the surface of collagen (15, 27).
Attachment to these adhesion molecules may be critical in the spread
and survival of B. burgdorferi in the joint. Furthermore, it
has recently been proposed that autoimmunity develops within the
proinflammatory milieu of the joints in genetically susceptible
patients with Lyme arthritis because of molecular mimicry between a
dominant T-cell epitope of outer-surface protein A (OspA) of B. burgdorferi and LFA-1 (14). Thus, the expression of
adhesion molecules may have specific pathologic consequences in Lyme arthritis.
The histopathological appearance of the synovial lesion in Lyme
arthritis, which includes synovial hyperplasia, vascular proliferation, and lymphoid infiltrates, is similar to that seen in other chronic inflammatory arthritides, including rheumatoid arthritis
(32). In rheumatoid arthritis, adhesion molecules,
including P-selectin, LFA-1, ICAM-1, VLA-4, and VCAM-1, are
up-regulated within the intense proinflammatory milieu of the synovial
lesion (16, 20, 36). In addition, in the murine model of
acute Lyme arthritis, P-selectin, ICAM-1, and VCAM-1 are upregulated in
B. burgdorferi-infected synovia (4, 29).
However, there is currently no animal model of treatment-resistant Lyme
arthritis. We describe here the expression of adhesion molecules in
synovial tissues from patients with treatment-resistant Lyme arthritis
compared with that in patients with rheumatoid arthritis or chronic
inflammatory monoarthritis.
 |
MATERIALS AND METHODS |
Patients.
For this study, we tested archival synovial tissue
specimens from 29 patients with treatment-resistant Lyme arthritis
obtained during a 20-year period (1978 to 1998). The patients met the
Centers for Disease Control and Prevention (CDC) criteria for the
diagnosis of Lyme arthritis. They had swollen knees and positive
antibody responses to B. burgdorferi by enzyme-linked
immunosorbent assay and Western blotting, interpreted according to the
Centers for Disease Control-Association of State and Territorial Public
Health Laboratory Directors criteria (6, 7). Their ages
ranged from 10 to 66 years (median, 36 years); 15 were female, and 14 were male. The median duration from the onset of arthritis to synovectomy was 12 months (range, 6 to 96 months). All 29 patients were
treated for their arthritis with antibiotic therapy, usually oral
doxycycline and intravenous ceftriaxone for 30 days each. The median
elapsed time from antibiotic treatment to synovectomy was 5 months. At
that time, B. burgdorferi DNA was not detectable in the
synovial samples (5). The comparison groups included synovial samples from eight patients with idiopathic, chronic inflammatory monoarthritis (the inflammatory arthritis group), six
patients with rheumatoid arthritis, and one patient with juvenile rheumatoid arthritis (the rheumatoid arthritis group).
Histopathology.
All tissue specimens were frozen in
optimal-cutting-temperature compound (Tissue-Tek; Miles, Inc.,
Diagnostic Division, Elkhardt, Ind.) and stored in liquid nitrogen.
Serial 6-µm-thick cryostat sections from each patient were mounted on
Superfrost Plus slides (Fisher Scientific, Pittsburgh, Pa.); they were
air dried and fixed in cold acetone for 10 min. The slides were then
stored at
70°C until use. The first slide in the series was stained with hematoxylin-eosin to determine the general cellular architecture.
Monoclonal antibodies.
We selected monoclonal antibodies
that identify cell surface markers, selectins, integrins, and adhesion
molecules of the immunoglobulin superfamily, as described in Table
1. In preliminary experiments, tonsillar
tissue was used to determine the optimal concentration of each antibody
that achieved maximal staining sensitivity with minimal background.
Immunohistochemistry.
Immunoperoxidase staining was done
with a Vectastain ABC kit (Vector Laboratories, Burlingame, Calif.).
The slides were brought to room temperature, briefly soaked in
phosphate-buffered saline, and then blocked for 20 min with normal
horse serum. Subsequent incubations were carried out with primary
monoclonal antibodies, a biotinylated secondary antibody, Vectastain
ABC Reagent, and the chromogen substrate 3 diamino-benzidine-tetra-HCl
(DAB, Acros, N.J.). After final rinsing with tap water, the slides were
counterstained with hematoxylin (Fisher Scientific, Fair Lawn, N.J.)
and mounted with Cytoseal (Stephens Scientific, Riverdale, N.J.). A
negative control section, stained with isotype-specific irrelevant
primary antibody, was included on each slide.
Grading system and statistical analysis.
The series of
slides from each patient were graded by two blinded observers. The
expression of each adhesion molecule and cell marker was scored on a
scale of 0 to 3 as absent (0), mild (1), moderate (2), or marked (3).
When the two observers assigned different scores to a slide, it was
reviewed by both observers together and a final score was agreed upon.
The average scores for each adhesion molecule or cell marker tested
were compared between the patients with Lyme arthritis and those with
rheumatoid arthritis or chronic inflammatory monoarthritis by analysis
of variance. Results are expressed as means ± one standard deviation.
 |
RESULTS |
Organization of the cellular components in synovium.
In
hematoxylin-eosin-stained sections, synovial samples from the 29 patients with treatment-resistant Lyme arthritis showed moderate-to-marked synovial lining cell hyperplasia, synovial cell
hyperplasia, vascular proliferation, and infiltrates of mononuclear cells (Fig 1A and B). The intensity of
mononuclear cell infiltration in the subsynovial lining areas varied
greatly among individual patients. Fifteen of the 29 patients had
lymphoid aggregates, whereas 10 patients had diffuse or scattered
infiltrates without aggregates and 4 had hypertrophied synovium with
few lymphocytes. Similarly, synovial samples from the seven
patients with rheumatoid arthritis and the eight patients with chronic
inflammatory monoarthritis showed moderate-to-marked synovial cell
hyperplasia, vascular proliferation, and a range of lymphoid
infiltration. The overall grades for each of these features were
similar in the three patient groups (Table
2).

View larger version (110K):
[in this window]
[in a new window]
|
FIG. 1.
The cellular architecture and infiltrating cells are
shown in serial frozen sections of synovial tissue from the knee joint
of a patient with treatment-resistant Lyme arthritis. In
hematoxylin-eosin-stained sections (A and B), villous hypertrophy,
synovial cell hyperplasia, vascular proliferation, and infiltrating
cells are seen. In sections stained with monoclonal antibodies to cell
surface markers (brown color), CD14+ synovial cells of
macrophage lineage and infiltrating macrophages are seen throughout the
synovial sublining areas (C), CD3+ T cells are seen
diffusely in synovial sublining areas (D) and in clusters (E), and
CD20+ B cells are found primarily in lymphoid aggregates
(F). Panels D to F are centered on the same aggregate. The nonspecific
background stain is hematoxylin (purple color). Magnifications, ×100
(A and D), ×200 (C), and ×400 (B, E, and F).
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Comparison of synovial histologies and adhesion molecule
expression levels in patients with Lyme arthritis, rheumatoid
arthritis, or idiopathic, chronic inflammatory
monoarthritisa
|
|
In immunoperoxidase-stained sections, the organizations of the cellular
infiltrate and the numbers of each cell type, determined
with
monoclonal antibodies to cell surface markers, were also
similar in
synovia from patients with Lyme arthritis, rheumatoid
arthritis, or
chronic inflammatory monoarthritis (Table
2). CD14
+
macrophages were scattered throughout the synovial sublining
areas, and
synovial cells of macrophage lineage also bore this
marker (Fig.
1C).
CD3
+ T cells were found in a patchy or diffuse
distribution in synovial
sublining areas (Fig.
1D). Among the patients
with lymphoid aggregates,
tightly mixed clusters of CD20
+ B
cells and CD3
+ T cells were seen (Fig.
1E and F). A few
scattered B cells were
sometimes seen in other
locations.
Vascular adhesion molecules.
The Lyme arthritis synovia
showed vascular proliferation with moderate-to-marked
expression of P-selectin and vascular adhesion protein-1
(VAP-1) (Fig. 2). P-selectin was
expressed exclusively on platelets and endothelial cells in the
microvasculature. Antibody to VAP-1 stained the smooth muscle fibers in
the larger venules as well as the cuboidal endothelium and connective
tissue in high endothelial venules, which resulted in a thicker
appearance of the vessels. There were no significant differences among
the three patient groups in the levels of expression of these vascular
adhesion molecules (Table 2).

View larger version (120K):
[in this window]
[in a new window]
|
FIG. 2.
Vascular markers (brown color) are shown in frozen
tissue sections of synovial tissue from the knee joints of patients
with treatment-resistant Lyme arthritis. The nonspecific background
stain is hematoxylin (purple color). VAP-1 is seen on the cuboidal
endothelium and deeper layers of high endothelial venules (A and B).
P-selectin is seen exclusively on the endothelial cells in the
capillaries and several larger vessels (C and D). Magnifications, ×100
(A and C) and ×400 (B and D).
|
|
Intercellular adhesion markers.
The Lyme arthritis synovia
showed moderate-to-marked expression of LFA-1 on infiltrating cells,
especially on lymphocytes in clusters or perivascular locations.
In addition, widespread expression of its ligand, ICAM-1, was
seen in endothelium, synoviocytes, and lymphocytes (Fig.
3). Levels of
expression of these two adhesion molecules were similar among the three
patient groups (Table 2). Most of the Lyme arthritis patients also had
mild-to-moderate expression of VLA-4, particularly in perivascular
lymphoid infiltrates and less often in the synovial lining (Fig. 3E and
F). However, 7 of the 29 synovial samples (24%) from patients with
Lyme arthritis had no discernible expression of VLA-4 whereas all 15 patients in the comparison groups showed mild-to-marked staining of
this adhesion molecule. Therefore, the mean score for VLA-4 expression among Lyme arthritis patients tended to be less than those for the
other two groups (P = 0.19). VCAM-1, the ligand of VLA-4, was most prominently expressed in synovial lining cells (Fig. 3G and
H). However, in some patients, the staining was more diffuse and
included endothelial cells and inflammatory cells. The mean expression
of VCAM-1 was significantly less in Lyme arthritis patients than in the
comparison groups by analysis of variance (P = 0.006)
(Table 2).

View larger version (138K):
[in this window]
[in a new window]
|
FIG. 3.
Similar levels of expression of intercellular adhesion
molecules (brown color) in frozen tissue sections of synovial tissue
from patients with treatment-resistant Lyme arthritis (left panels) and
rheumatoid arthritis (right panels). The nonspecific background stain
is hematoxylin (purple color). LFA-1 expression is marked on
infiltrating cells, especially in lymphocyte clusters in the synovial
sublining and perivascular areas (A and B); ICAM-1 expression is
widespread in synoviocytes, lymphocytes, and vessel endothelium (C and
D); VLA-4 is expressed most in perivascular lymphoid infiltrates and some synoviocytes (E
and F); and VCAM-1 expression on fibroblast-like synoviocytes is
moderate in patients with treatment-resistant Lyme arthritis (G) and
marked in patients with rheumatoid arthritis (H). Note that the extent
of VCAM-1 expression is limited to synoviocytes in panel G but includes
the endothelium of the vessel in the upper right-hand corner of panel
H. Magnifications, ×200 (A to D and G to H) and ×400 (E and F).
|
|
 |
DISCUSSION |
In this study, we describe the inflammatory infiltrate, cellular
markers, and adhesion molecules in the synovia of patients with
treatment-resistant Lyme arthritis or other chronic inflammatory arthritides. In an initial histopathologic study (19), we
described the synovial lesions in patients with Lyme arthritis compared with those in patients with many other types of arthritis. A marked similarity was noted in the synovial architecture and cellular infiltrates in the chronic inflammatory arthritides, including Lyme
arthritis and rheumatoid arthritis. In addition, Lyme synovia showed
striking deposition of fibrin and a form of endarteritis obliterans,
which was not seen in other synovial diseases. Subsequently, we
identified lymphoid cell surface markers in Lyme synovia compared with
those in rheumatoid synovia and tonsillar lymphoid tissue (32). Again, the synovial lesions in both Lyme and
rheumatoid synovia were similar and often consisted of the elements
found in normal organized lymphoid tissue. In both diseases, T cells, predominantly of the CD4+ helper cell subset, were
distributed diffusely in the subsynovial lining areas, often with
nodular aggregates of tightly intermixed T and B cells. HLA-DR and DQ
expression was intense throughout the lesions. Later, using in
situ hybridization with cytokine-specific riboprobes, we examined
the expression of cytokine mRNA in synovia from patients with
chronic Lyme arthritis, rheumatoid arthritis, or juvenile
rheumatoid arthritis. Patients in each group had prominent expression of proinflammatory cytokines, with less intense expression of anti-inflammatory cytokines (17). This proinflammatory
response may be critical in the development of autoimmunity within the joint.
In this study of patients with treatment-resistant Lyme arthritis,
rheumatoid arthritis, or chronic inflammatory monoarthritis, P-selectin
was highly expressed on capillary vessels in synovia in each of the
three patient groups. This adhesion molecule, which binds
Sialyl-Lewisx protein and P-selectin glycoprotein ligand-1
on leukocyte cell membranes, is critical in the homing of monocytes to
synovial tissue (28, 31). Another vascular marker, VAP-1,
which is a unique sialoglycoprotein on vascular endothelium and smooth muscle cells, was expressed intensely in high endothelial venules, which are critical in leukocyte extravasation. VAP-1 has been implicated in the homing of small lymphocytes to synovia in patients with reactive arthritis or inflammatory bowel disease-associated arthritis (2, 28). We do not yet know from functional
studies whether these adhesion molecules play the same role in
lymphocyte and monocyte homing in Lyme arthritis as in reactive
arthritis, but both molecules are highly expressed in Lyme synovia.
Both LFA-1-ICAM-1 and VLA-4-VCAM-1 interactions are important in the
firm attachment of leukocytes to endothelial surfaces and in cell
signaling in inflamed synovium. Moreover, the binding of
LFA-1-ICAM-1 and VLA-4-VCAM-1 help to regulate each other
(8, 26), an "integrin cross talk" which is
necessary for the multistep process of leukocyte migration into
inflamed tissues (31). LFA-1 is constitutively expressed
on all circulating leukocytes, whereas ICAM-1 is found on synovial
cells of macrophage lineage and on vascular endothelium cells and
leukocytes (23). Antibodies against these molecules
strongly inhibit leukocyte migration into synovial tissue (13,
36). Both LFA-1 and ICAM-1 were intensely expressed in synovia
from patients with the three diseases studied here.
Although VLA-4 and its ligand VCAM-1 were also strongly expressed in
rheumatoid and chronic monoarthritis synovia, VCAM-1 expression was
less in Lyme synovia than in the other two chronic inflammatory
arthritides. VLA-4 is constitutively expressed on lymphocytes,
monocytes, and eosinophils, whereas VCAM-1 is expressed on
endothelial cells and fibroblast-like synovial lining cells. In
addition to interacting with VCAM-1, VLA-4 binds to fibronectin, a
matrix protein (1, 12, 24). Perhaps
VLA-4-fibronectin interactions, rather than VLA-1-VCAM-1
interactions, account for the fact that VLA-4 expression seemed greater
than VCAM-1 expression in Lyme synovia. Alternatively, this finding may
reflect certain differences in cytokine profiles in these diseases.
Tumor necrosis factor alpha up-regulates the expression of ICAM-1 and
VCAM-1, whereas gamma interferon up-regulates only the expression of
ICAM-1 (3, 25, 30). Using in situ hybridization, mRNA
for gamma interferon was prominent in Lyme synovia, which may be less
the case in rheumatoid synovia (17). Finally, this
difference may be a reflection of the duration of synovitis, which was
about 1 year in the Lyme arthritis group. Although the duration of
arthritis was probably longer among patients in the comparison groups,
clinical information was not available for these patients.
We were particularly interested in the expression of LFA-1 in synovium
because of the recent postulate that molecular mimicry between a
dominant T-cell epitope of OspA165-173 of B. burgdorferi and LFA-1
332-340 may induce
autoimmunity in genetically susceptible patients with Lyme arthritis
(14). An important component of the postulate is that
LFA-1 on T cells is up-regulated within the inflamed joint, so that
phagocytosis of apoptotic T cells by macrophages may lead to
presentation of the LFA-1
332-340 peptide. Some of the
OspA165-173-reactive T cells may then be stimulated not
only by the OspA peptide, but also by the cross-reactive LFA-1 epitope.
After the elimination of B. burgdorferi from the joints with
antibiotics, OspA-primed T cells may remain activated for some time by
the presentation of the cross-reactive LFA-1 peptide. The present
study demonstrates the intense expression of LFA-1 on T cells among
patients with antibiotic treatment-resistant Lyme arthritis.
However, it is not yet possible to demonstrate whether major
histocompatibility complex class II molecules in the lesion actually
present the LFA-1
332-340 peptide.
In summary, certain adhesion molecules, including LFA-1 and its main
ligand, ICAM-1, were intensely expressed in synovial samples from
patients with antibiotic treatment-resistant Lyme arthritis. Except for
the lesser expression of VCAM-1 in Lyme synovia, the levels of
expression of adhesion molecules were similar in the three patient
groups. Up-regulation of LFA-1 on lymphocytes in Lyme synovia may be
critical in the pathogenesis of treatment-resistant Lyme arthritis.
 |
ACKNOWLEDGMENTS |
This study was supported by grant AR-20358 from the National
Institutes of Health, the Eshe Fund, the Lyme/Arthritis Research Foundation, and the Mathers Foundation. E.A. received support from the
Lincoln National Foundation of Fort Wayne, Ind.
We thank Human Cooperative Tissue Network for providing synovial
samples from patients with rheumatoid arthritis, Sirpa Jalkanen for
providing the monoclonal antibody to VAP-1, Lisa Glickstein and
Jennifer Coburn for help with study design and methodology, Robin
Ruthazer for statistical support, and Hugh Wolfe for help with photography.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Division of
Rheumatology/Immunology, New England Medical Center, NEMC no. 406, 750 Washington St., Boston, MA 02111. Phone: (617) 636-5951. Fax: (617)
636-4252. E-mail: uakin{at}lifespan.org.
Editor:
W. A. Petri Jr.
 |
REFERENCES |
| 1.
|
Alon, R.,
P. D. Kassner,
M. W. Carr,
E. B. Finger,
M. E. Hemler, and T. A. Springer.
1995.
The integrin VLA-4 supports tethering and rolling in flow on VCAM-1.
J. Cell Biol.
128:1243-1253[Abstract/Free Full Text].
|
| 2.
|
Arvilommi, A. M.,
M. Salmi, and S. Jalkanen.
1997.
Organ-selective regulation of vascular adhesion protein-1 expression in man.
Eur. J. Immunol.
27:1794-1800[Medline].
|
| 3.
|
Blue, M. L.,
P. Conrad,
D. L. Webb,
T. Sarr, and M. Macaro.
1993.
Interacting monocytes and synoviocytes induce adhesion molecules by a cytokine-regulated process.
Lymphokine Cytokine Res.
12:213-218[Medline].
|
| 4.
|
Boeggemeyer, E.,
T. Stehle,
U. E. Schaible,
M. Hahne,
D. Vestweber, and M. M. Simon.
1994.
Borrelia burgdorferi upregulates the adhesion molecules E-selectin, P-selectin, ICAM-1, and VCAM-1 on mouse endothelioma cells in vitro.
Cell Adhes. Commun.
2:145-157[Medline].
|
| 5.
|
Carlson, D.,
J. Hernandez,
B. J. Bloom,
J. Coburn,
J. M. Aversa, and A. C. Steere.
1999.
Lack of Borrelia burgdorferi DNA in synovial samples in patients with antibiotic treatment-resistant Lyme arthritis.
Arthritis Rheum.
42:2705-2709[CrossRef][Medline].
|
| 6.
|
Centers for Disease Control and Prevention.
1990.
Case definition for public health surveillance.
Morb. Mortal. Wkly. Rep.
39:19-21[Medline].
|
| 7.
|
Centers for Disease Control and Prevention.
1995.
Recommendations for test performance and interpretation from the Second National Conference on the Serological Diagnosis of Lyme Disease.
Morb. Mortal. Wkly. Rep.
44:590-591[Medline].
|
| 8.
|
Chan, J. R.,
S. J. Hyduk, and M. I. Cybulsky.
2000.
VLA-4/VCAM-1 interaction activates LFA-1 mediated adhesion to ICAM-1 in human T cells.
J. Immunol.
164:746-753[Abstract/Free Full Text].
|
| 9.
|
Coburn, J.,
S. W. Barthold, and J. M. Leong.
1994.
Diverse Lyme disease spirochetes bind integrin IIb 3 on human platelets.
Infect. Immun.
12:5559-5567.
|
| 10.
|
Coburn, J.,
L. Magoun,
S. C. Bodary, and J. M. Leong.
1998.
Integrins v 3 and 5 1 mediate attachment of Lyme disease spirochetes to human cells.
Infect. Immun.
66:1946-1952[Abstract/Free Full Text].
|
| 11.
|
Dennis, D. T.
1998.
Epidemiology, ecology, and prevention of Lyme disease, p. 7-34.
In
D. W. Rahn, and J. Evans (ed.), Lyme disease. American College of Physicians, Philadelphia, Pa.
|
| 12.
|
Elices, M. J.,
V. Tsai,
D. Strahl,
A. S. Goel,
V. Tolletson,
T. Arrhenius,
E. A. Wayner,
F. C. A. Gaeta, and G. S. Firestein.
1994.
Expression and functional significance of alternatively spliced CS1 fibronectin in rheumatoid arthritis microvasculature.
J. Clin. Investig.
93:405-416.
|
| 13.
|
Grober, J. S.,
B. L. Bowen,
H. Ebling,
B. Athey,
C. B. Thompson,
D. A. Fox, and L. M. Stoolman.
1993.
Monocyte-endothelial adhesion in chronic rheumatoid arthritis.
J. Clin. Investig.
91:2609-2619.
|
| 14.
|
Gross, D. M.,
T. Forsthuber,
M. Tary-Lehman,
C. Etling,
I. Koichi,
Z. A. Nagy,
J. A. Field,
A. C. Steere, and B. T. Huber.
1998.
Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis.
Science
281:703-706[Abstract/Free Full Text].
|
| 15.
|
Guo, B. P.,
S. J. Norris,
L. C. Rosenberg, and M. Hook.
1995.
Adherence of Borrelia burgdorferi to the proteoglycan decorin.
Infect. Immun.
63:3467-3472[Abstract].
|
| 16.
|
Hale, L. P.,
M. E. Martin,
D. E. McCollum,
J. A. Nunley,
T. A. Springer,
K. H. Singer, and B. F. Haynes.
1989.
Immunohistologic analysis of the distribution of cell adhesion molecules within the inflammatory synovial microenvironment.
Arthritis Rheum.
32:22-30[Medline].
|
| 17.
|
Harjacek, M.,
S. Diaz-Cano,
B. A. Alman,
J. Coburn,
R. Ruthazer,
H. Wolfe, and A. C. Steere.
2000.
Prominent expression of mRNA for proinflammatory cytokines in synovium in patients with juvenile rheumatoid arthritis or chronic Lyme arthritis.
J. Rheumatol.
27:497-503[Medline].
|
| 18.
|
Janeway, C. A.,
P. Travers,
M. Walport, and J. D. Capra.
1999.
T-cell mediated immunity, p. 266-268.
In
P. Austin, E. Lawrence, B. Goatly, and E. Hunt (ed.), Immunobiology: the immune system in health and disease, 4th ed. Elsevier Science Ltd., London, United Kingdom.
|
| 19.
|
Johnston, Y. E.,
P. H. Duray,
A. C. Steere,
M. Kashgarian,
J. Buza,
S. E. Malawista, and P. W. Askenase.
1985.
Lyme arthritis. Spirochetes found in synovial microangiopathic lesions.
Am. J. Pathol.
118:26-34[Abstract].
|
| 20.
|
Littler, A. J.,
C. D. Buckley,
P. Wordsworth,
I. Collins,
J. Martinson, and D. L. Simmons.
1997.
A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis.
Br. J. Rheumatol.
36:164-169[Abstract/Free Full Text].
|
| 21.
|
McMurray, R. W.
1996.
Adhesion molecules in autoimmune disease.
Semin. Arthritis Rheum.
25:215-234[CrossRef][Medline].
|
| 22.
|
Meerschaert, J., and M. B. Furie.
1994.
Monocytes use either CD11/CD18 or VLA-4 to migrate across human endothelium in vitro.
J. Immunol.
152:1915-1926[Abstract].
|
| 23.
|
Mojcik, C. F., and E. M. Shevach.
1997.
Adhesion molecules: a rheumatologic perspective.
Arthritis Rheum.
40:991-1004[Medline].
|
| 24.
|
Mueller-Ladner, U.,
M. J. Elices,
J. B. Kriegsmann,
D. Strahl,
R. E. Gay,
G. S. Firestein, and S. Gay.
1997.
Alternatively spliced CS-1 fibronectin isoform and its receptor VLA-4 in rheumatoid arthritis synovium.
J. Rheumatol.
24:1873-1880[Medline].
|
| 25.
|
Oksi, J.,
J. Savolainen,
J. Pene,
J. Bousquet,
P. Laippala, and M. K. Viljanen.
1996.
Decreased interleukin-4 and increased gamma interferon production by peripheral blood mononuclear cells of patients with Lyme borreliosis.
Infect. Immun.
64:3620-3623[Abstract].
|
| 26.
|
Porter, J. C., and N. Hogg.
1997.
Integrin cross talk: activation of lymphocyte function associated antigen-1 on human T cells alters VLA-4 and VLA-5 mediated function.
J. Cell Biol.
138:1437-1447[Abstract/Free Full Text].
|
| 27.
|
Probert, W. S., and B. J. B. Johnson.
1998.
Identification of a 47kDa fibronectin-binding protein expressed by Borrelia burgdorferi isolate B31.
Mol. Microbiol.
30:1003-1015[CrossRef][Medline].
|
| 28.
|
Salmi, M.,
P. Rajala, and S. Jalkanen.
1997.
Homing of mucosal leukocytes to joints. Distinct endothelial ligands in synovium mediate leukocyte subtype specific adhesion.
J. Clin. Investig.
99:2165-2172[Medline].
|
| 29.
|
Schaible, U. E.,
D. Vestweber,
E. G. Butcher,
T. Stehle, and M. M. Simon.
1994.
Expression of endothelial cell adhesion molecules in joints and heart during Borrelia burgdorferi infection of mice.
Cell Adhes. Commun.
2:465-479[Medline].
|
| 30.
|
Spoelstra, F. M.,
D. S. Postma,
H. Hovenga,
J. A. Noordhoek, and H. F. Kauffman.
1999.
Interferon-gamma and interleukin-4 differentially regulate ICAM-1 and VCAM-1 expression in human lung fibroblasts.
Eur. Res. J.
14:759-766.
|
| 31.
|
Springer, T. A.
1994.
Traffic signals for lymphocyte emigration: the multistep paradigm.
Cell
76:301-314[CrossRef][Medline].
|
| 32.
|
Steere, A. C.,
P. H. Duray, and E. C. Butcher.
1988.
Spirochetal antigens and lymphoid cell surface markers in Lyme synovitis.
Arthritis Rheum.
31:487-495[Medline].
|
| 33.
|
Steere, A. C.,
J. Green,
R. T. Schoen,
E. Taylor,
G. J. Hutchinson,
D. W. Rahn, and S. E. Malawista.
1985.
Successful parenteral penicillin therapy of established Lyme arthritis.
N. Engl. J. Med.
312:869-874[Abstract].
|
| 34.
|
Steere, A. C.,
R. E. Levin,
P. J. Molloy,
R. A. Kalish,
J. H. Abraham III,
N. Y. Liu, and C. H. Schmid.
1994.
Treatment of Lyme arthritis.
Arthritis Rheum.
37:878-888[Medline].
|
| 35.
|
Steere, A. C.,
R. T. Schoen, and E. Taylor.
1987.
The clinical evolution of Lyme arthritis.
Ann. Intern. Med.
107:725-731.
|
| 36.
|
van Dinther-Janssen, A. C. H. M.,
G. Kraal,
R. M. van Soesbergen,
R. J. Scheper, and C. J. L. M. Meijer.
1994.
Immunohistological and functional analysis of adhesion molecule expression in the rheumatoid synovial lining layer. Implications for synovial lining cell destruction.
J. Rheumatol.
21:1998-2004[Medline].
|
Infection and Immunity, March 2001, p. 1774-1780, Vol. 69, No. 3
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.3.1774-1780.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Noda, K., She, H., Nakazawa, T., Hisatomi, T., Nakao, S., Almulki, L., Zandi, S., Miyahara, S., Ito, Y., Thomas, K. L., Garland, R. C., Miller, J. W., Gragoudas, E. S., Mashima, Y., Hafezi-Moghadam, A.
(2008). Vascular adhesion protein-1 blockade suppresses choroidal neovascularization. FASEB J.
22: 2928-2935
[Abstract]
[Full Text]
-
Noda, K., Miyahara, S., Nakazawa, T., Almulki, L., Nakao, S., Hisatomi, T., She, H., Thomas, K. L., Garland, R. C., Miller, J. W., Gragoudas, E. S., Kawai, Y., Mashima, Y., Hafezi-Moghadam, A.
(2008). Inhibition of vascular adhesion protein-1 suppresses endotoxin-induced uveitis. FASEB J.
22: 1094-1103
[Abstract]
[Full Text]
-
Nardelli, D. T., Callister, S. M., Schell, R. F.
(2008). Lyme Arthritis: Current Concepts and a Change in Paradigm. CVI
15: 21-34
[Full Text]
-
Mullegger, R. R., Means, T. K., Shin, J. J., Lee, M., Jones, K. L., Glickstein, L. J., Luster, A. D., Steere, A. C.
(2007). Chemokine Signatures in the Skin Disorders of Lyme Borreliosis in Europe: Predominance of CXCL9 and CXCL10 in Erythema Migrans and Acrodermatitis and CXCL13 in Lymphocytoma. Infect. Immun.
75: 4621-4628
[Abstract]
[Full Text]
-
Ghosh, S., Seward, R., Costello, C. E., Stollar, B. D., Huber, B. T.
(2006). Autoantibodies from Synovial Lesions in Chronic, Antibiotic Treatment-Resistant Lyme Arthritis Bind Cytokeratin-10. J. Immunol.
177: 2486-2494
[Abstract]
[Full Text]
-
Glasner, J., Blum, H., Wehner, V., Stilz, H. U., Humphries, J. D., Curley, G. P., Mould, A. P., Humphries, M. J., Hallmann, R., Rollinghoff, M., Gessner, A.
(2005). A Small Molecule {alpha}4{beta}1 Antagonist Prevents Development of Murine Lyme Arthritis without Affecting Protective Immunity. J. Immunol.
175: 4724-4734
[Abstract]
[Full Text]
-
Guerau-de-Arellano, M., Alroy, J., Huber, B. T.
(2005). {beta}2 Integrins Control the Severity of Murine Lyme Carditis. Infect. Immun.
73: 3242-3250
[Abstract]
[Full Text]
-
Ghosh, S., Steere, A. C., Stollar, B. D., Huber, B. T.
(2005). In Situ Diversification of the Antibody Repertoire in Chronic Lyme Arthritis Synovium. J. Immunol.
174: 2860-2869
[Abstract]
[Full Text]
-
Amedei, A., Bergman, M. P., Appelmelk, B. J., Azzurri, A., Benagiano, M., Tamburini, C., van der Zee, R., Telford, J. L., Vandenbroucke-Grauls, C. M.J.E., D'Elios, M. M., Del Prete, G.
(2003). Molecular Mimicry between Helicobacter pylori Antigens and H+,K+-Adenosine Triphosphatase in Human Gastric Autoimmunity. JEM
198: 1147-1156
[Abstract]
[Full Text]